HomeCompareGRWXF vs MRK

GRWXF vs MRK: Dividend Comparison 2026

GRWXF yields 33.33% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRWXF wins by $103.4K in total portfolio value
10 years
GRWXF
GRWXF
● Live price
33.33%
Share price
$6.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$160.1K
Annual income
$23,203.52
Full GRWXF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — GRWXF vs MRK

📍 GRWXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRWXFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRWXF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRWXF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRWXF
Annual income on $10K today (after 15% tax)
$2,833.33/yr
After 10yr DRIP, annual income (after tax)
$19,722.99/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, GRWXF beats the other by $11,394.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRWXF + MRK for your $10,000?

GRWXF: 50%MRK: 50%
100% MRK50/50100% GRWXF
Portfolio after 10yr
$108.5K
Annual income
$16,500.83/yr
Blended yield
15.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GRWXF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.2
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRWXF buys
0
MRK buys
0
No recent congressional trades found for GRWXF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRWXFMRK
Forward yield33.33%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$160.1K$56.8K
Annual income after 10y$23,203.52$9,798.13
Total dividends collected$113.6K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: GRWXF vs MRK ($10,000, DRIP)

YearGRWXF PortfolioGRWXF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$14,033$3,333.33$11,206$366.19+$2.8KGRWXF
2$19,387$4,371.75$12,650$502.35+$6.7KGRWXF
3$26,389$5,644.57$14,407$694.19+$12.0KGRWXF
4$35,417$7,180.46$16,585$967.82+$18.8KGRWXF
5$46,902$9,006.44$19,342$1,363.89+$27.6KGRWXF
6$61,333$11,146.93$22,913$1,947.19+$38.4KGRWXF
7$79,249$13,622.82$27,662$2,823.89+$51.6KGRWXF
8$101,247$16,450.69$34,159$4,173.35+$67.1KGRWXF
9$127,976$19,642.17$43,337$6,308.80+$84.6KGRWXF
10$160,138$23,203.52$56,776$9,798.13+$103.4KGRWXF

GRWXF vs MRK: Complete Analysis 2026

GRWXFStock

Molten Ventures Plc, formerly known as Draper Esprit plc, is a private equity and venture capital firm specializing in any stage in the lifecycle of a business from seed and series A stage, growth capital to pre-IPO investments, late stage, cross-stage investments, buyouts, PIPES, and also makes direct and secondary investments in portfolio companies. It also seeks to buy entire funds from other tech investors. The firm primarily invests in companies from pre-revenue stage upwards. It primarily invests in technology oriented business. The firm typically invests in digital technology, consumer, commerce, enterprise and data, systems and semiconductors, financial technology, internet, mobile, media, telecom, consumer technology, enterprise technology, SaaS, fintech, deeptech, digital health & wellness and healthcare sectors, software, hardware, medical technology, and life sciences sectors. It invests in companies based in Europe, Ireland, and United Kingdom. The firm seeks to invest between $0.02 million and €10 million ($10.88 million) in rounds up to €1 million ($1.09 million) and €30 million ($32.63 million). It invests 30 percent of its corpus in very early stage companies with less than $5 million in revenues. The firm seeks to make minority and majority investments. Molten Ventures Plc was founded in 1984 and is based in London, United Kingdom with an additional offices in Dublin, Ireland.

Full GRWXF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this GRWXF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRWXF vs SCHDGRWXF vs JEPIGRWXF vs OGRWXF vs KOGRWXF vs MAINGRWXF vs JNJGRWXF vs ABBVGRWXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.